New formulation improves treatment of Hepatitis B
Researchers at the University of Nebraska Medical Center are developing promising new treatment strategies for Hepatitis B.
The innovation features injectable, long acting-slow release prodrug-based formulations of a class of antiviral drugs called thiazolides. The new formulation can be effectively packaged into nanoparticles that slowly release the active drug in a patient’s body.
The goal of this strategy is to create a once-a-month injectable formulation, or even a once every three- or six-month injectable formulation.
Currently, the researchers are developing prodrug formulations of nitazoxanide for testing in animal models of Hepatitis B infection.
They are also developing prodrug formulations of other anti-viral drugs such as nucleoside reverse transcriptase inhibitors, which can also treats Hepatitis B.
To discuss licensing opportunities contact Matt Boehm, Ph.D., at firstname.lastname@example.org or 402-559-2166.